Key Points
- Director Edward Ludwig bought 5,000 Boston Scientific shares at an average price of $45.48, investing $227,400 and increasing his holdings by 19.72% to 30,359 shares.
- Boston Scientific exceeded quarterly expectations, reporting adjusted EPS of $0.86 versus $0.83 expected and revenue of $5.44 billion, up 7.5% year over year. The company guided for third-quarter EPS of $0.80–$0.82 and full-year EPS of $3.28–$3.32.
- The company authorized a $5 billion share repurchase program, while analysts maintain a “Moderate Buy” consensus with an average price target of $71.62, despite several recent target reductions.
Boston Scientific Corporation (NYSE:BSX - Get Free Report) Director Edward Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction on Friday, July 31st. The shares were bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director owned 30,359 shares of the company's stock, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Boston Scientific Price Performance
Shares of NYSE BSX opened at $48.45 on Tuesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a market capitalization of $72.02 billion, a price-to-earnings ratio of 19.62, a PEG ratio of 1.02 and a beta of 0.56. The business has a 50-day moving average of $45.95 and a 200-day moving average of $61.70.
Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The company's revenue was up 7.5% on a year-over-year basis. During the same period last year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.
Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's leadership believes its shares are undervalued.
Hedge Funds Weigh In On Boston Scientific
A number of institutional investors have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. purchased a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $1,079,000. Mill Capital Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth approximately $9,851,000. Cary Street Partners Financial LLC increased its stake in shares of Boston Scientific by 16.7% in the second quarter. Cary Street Partners Financial LLC now owns 25,092 shares of the medical equipment provider's stock worth $1,071,000 after buying an additional 3,597 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in Boston Scientific by 28.9% in the second quarter. Farther Finance Advisors LLC now owns 28,699 shares of the medical equipment provider's stock valued at $1,227,000 after acquiring an additional 6,427 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its holdings in Boston Scientific by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 49,355 shares of the medical equipment provider's stock valued at $2,106,000 after acquiring an additional 1,119 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have recently commented on the stock. Wall Street Zen cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Sunday. Needham & Company LLC lowered their price target on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a report on Wednesday, July 8th. Leerink Partners set a $60.00 price target on shares of Boston Scientific in a research note on Thursday. Barclays cut their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an "overweight" rating on the stock in a report on Thursday, May 28th. Finally, Argus reissued a "hold" rating on shares of Boston Scientific in a research report on Friday. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $71.62.
Check Out Our Latest Stock Report on BSX
About Boston Scientific
(
Get Free Report)
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
